Nkarta (NKTX) Cash from Financing Activities (2019 - 2026)
Nkarta (NKTX) posted quarterly Cash from Financing Activities of $6000.0 for Q1 2026, down 90.62% quarter-over-quarter from $64000.0 in Q4 2025.
Nkarta (NKTX) Cash from Financing Activities (2019 - 2026) Analysis & Trends
Nkarta's Cash from Financing Activities history runs 8 years deep, the most recent figure standing at $6000.0 for Q1 2026.
- In Q1 2026, Cash from Financing Activities changed N/A year-over-year to $6000.0; the TTM figure through Mar 2026 stood at $147000.0 (up 180.77% YoY), while the FY2025 annual figure was $141000.0, down 99.94% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $6000.0, down from $64000.0 in the prior quarter.
- The five-year high for Cash from Financing Activities was $226.3 million in Q1 2024, with the low at -$368000.0 in Q2 2024.
- The 5-year median for Cash from Financing Activities is $131500.0 (2022), against an average of $31.9 million.
- Peak annual rise in Cash from Financing Activities reached 22626500.0% in 2024, while the deepest fall reached 193.16% in 2024.
- Nkarta's Cash from Financing Activities stood at $424000.0 in 2022, then tumbled by 30.42% to $295000.0 in 2023, then slumped by 37.63% to $184000.0 in 2024, then sank by 65.22% to $64000.0 in 2025, then slumped by 90.62% to $6000.0 in 2026.
- Business Quant data shows NKTX's Cash from Financing Activities at $6000.0 in Q1 2026, $64000.0 in Q4 2025, and $77000.0 in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Nkarta | 201.14 Mn | 201.14 Mn | - | 676,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 676,000.00 |
| Jun 30, 2026 | 676,000.00 |
| Mar 31, 2026 | 6,000.00 |
| Mar 31, 2026 | 6,000.00 |
| Dec 31, 2025 | 64,000.00 |
| Dec 31, 2025 | 64,000.00 |
| Jun 30, 2025 | 77,000.00 |
| Jun 30, 2025 | 77,000.00 |
| Dec 31, 2024 | 184,000.00 |
| Dec 31, 2024 | 184,000.00 |
| Sep 30, 2024 | 2,000.00 |
| Sep 30, 2024 | 2,000.00 |
| Jun 30, 2024 | -368,000.00 |
| Jun 30, 2024 | -368,000.00 |
| Mar 31, 2024 | 226.27 Mn |
| Mar 31, 2024 | 226.27 Mn |
| Dec 31, 2023 | 295,000.00 |
| Dec 31, 2023 | 295,000.00 |
| Jun 30, 2023 | 395,000.00 |
| Jun 30, 2023 | 395,000.00 |